Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 4.13T |
| Revenue (ttm) | 549.64B |
| Net Income (ttm) | 104.50B |
| Shares Out | 2.40B |
| EPS (ttm) | 43.55 |
| PE Ratio | 39.49 |
| Forward PE | 34.30 |
| Dividend | 16.00 (0.93%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 877,515 |
| Average Volume | 1,924,526 |
| Open | 1,720.00 |
| Previous Close | 1,719.70 |
| Day's Range | 1,708.90 - 1,726.00 |
| 52-Week Range | 1,548.00 - 1,902.95 |
| Beta | 0.16 |
| RSI | 39.47 |
| Earnings Date | Feb 5, 2026 |
About NSE:SUNPHARMA
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respira... [Read more]
Financial Performance
In 2024, NSE:SUNPHARMA's revenue was 525.78 billion, an increase of 8.42% compared to the previous year's 484.97 billion. Earnings were 109.29 billion, an increase of 14.12%.
Financial StatementsNews
Dr Reddy, Cipla, Sun Pharma and other stocks in focus today as Govt bans high-dose Nimesulide formulations
Shares of several pharmaceutical companies are likely to remain in focus after the Ministry of Health and Family Welfare (MoHFW)...
Sun Pharma may face low double-digit EPS hit in worst case, says Kotak
Kotak Institutional Equities has maintained its add rating on Sun Pharma with a target price of ₹1,975, warning that newly...
Nifty 50 top losers today, December 18: Sun Pharma, Tata Steel, Power Grid, Asian Paints, Tata Consumer Products and more
Indian equity benchmarks closed marginally lower after a volatile trading session on December 18, with selling pressure in several heavyweight...
Sun Pharma shares fall over 2% after US FDA issues OAI status for Baska facility
Sun Pharmaceutical Industries’ shares slipped more than 2% after the company disclosed that the US Food and Drug Administration (US...
Sun Pharma receives US FDA OAI status for Baska facility after Inspection
Sun Pharmaceutical Industries Ltd has informed the stock exchanges that the US Food and Drug Administration (US FDA) has classified...
Nifty 50 top losers today, December 12: Hindustan Unilever, Max Healthcare Institute, Sun Pharma, ITC, Asian Paints and more
Indian equity indices ended Thursday’s session on a steady positive note, with the Nifty closing 0.57% higher at 26,046.95 and...
Nifty 50 top gainers today, December 10: Eicher Motors, Hindalco Industries, HDFC Life, Tata Steel, Sun Pharma and more
Indian equity benchmarks closed lower on December 10, with the Nifty settling at 25,758 and the Sensex declining 275 points...
Novo Nordisk moves Delhi HC to bar Sun Pharma from manufacturing semaglutide; Hearing expected tomorrow
Danish drugmaker Novo Nordisk has approached the Delhi High Court seeking to restrain Sun Pharmaceutical Industries from manufacturing semaglutide, a...
Sun Pharma shares in focus as Novo Nordisk moves HC to block firm from manufacturing semaglutide
Shares of Sun Pharmaceutical Industries were trading mildly lower on Monday, slipping 0.42% to Rs 1,788.70 as of 11:08 AM,...
Nifty 50 top losers today, December 1: Max Healthcare, InterGlobe Aviation, Bajaj Finance, Sun Pharma, Adani Enterprises and more
Indian equity benchmarks spent much of the December 1 session moving within a narrow band, eventually closing almost unchanged. The...
Sun Pharma launches Ilumya in India for moderate-to-severe plaque psoriasis – clinical data shows strong long-term efficacy
Sun Pharmaceutical Industries Ltd has officially introduced its global innovative biologic Ilumya® (Tildrakizumab) in India for the treatment of moderate-to-severe...
Nifty 50 top gainers today, November 28: Mahindra & Mahindra, Sun Pharmaceutical, Adani Enterprises, Dr. Reddy’s Laboratories and more
Indian equity benchmarks ended almost unchanged on November 28. The Sensex slipped 0.02% to close at 85,706.67, while the Nifty...
Morgan Stanley bullish on Sun Pharma as FDA approval supports stronger specialty momentum
Morgan Stanley has reiterated its overweight stance on Sun Pharma with a target price of ₹2,026 per share after the...
Sun Pharma announces FDA approval for updated UNLOXCYT label based on long-term clinical data
Sun Pharmaceutical Industries Ltd has announced that the U.S. Food and Drug Administration (FDA) has approved an updated label for...
AstraZeneca Pharma India jumps 3% after teaming up with Sun Pharma to boost access to Hyperkalaemia treatment in India
AstraZeneca Pharma India shares rose more than 3% in morning trade after the company, along with Sun Pharmaceutical Industries, announced...
AstraZeneca and Sun Pharma partner to boost access to Hyperkalaemia treatment in India
AstraZeneca Pharma India and Sun Pharmaceutical Industries have joined hands once again, announcing a second brand partnership to expand the...
Why are Sun Pharma shares falling today? Explained
Shares of Sun Pharmaceutical Industries Ltd fell to Rs 1,712.20 on Tuesday after the company’s partner Philogen S.p.A. announced that its...
Sun Pharma’s partner Philogen reports positive survival trends in Fibromun Phase III study for soft tissue sarcoma
Shares of Sun Pharmaceutical Industries will be in focus on Wednesday, November 12, after the company announced that its partner...
Sun Pharma share: Nomura upgrades to buy, expects 16% upside on strong branded generics growth and favourable risk-reward
Nomura has upgraded Sun Pharma to a buy call with a target price of ₹1,960 per share, implying a potential...
Sun Pharmaceuticals Industries Ltd (BOM:524715) Q2 2026 Earnings Call Highlights: Strong Sales ...
Sun Pharmaceuticals Industries Ltd (BOM:524715) Q2 2026 Earnings Call Highlights: Strong Sales Growth Amidst US Market Challenges
Q2 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript
Q2 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript
Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect
Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeut...
Stocks to Watch Today, October 9: HFCL, Coal India, Prestige Estates, GR Infra, Lupin, Senco Gold, Saatvik Green, Adani Power, Sun Pharma in focus
Indian equities are set for a stock-specific session on Thursday, October 9, 2025, as several companies announced project wins, business...
Sun Pharma shares rally nearly 3% as Citi reiterates ‘Buy’ rating, says pricing overhangs now resolved after Pfizer deal
Sun Pharmaceutical Industries Ltd. shares surged nearly 3% on strong investor sentiment after Citi reiterated its buy rating for the stock, setting a target price of ₹2,180 per share. The brokerage hi...